R 1068

Drug Profile

R 1068

Latest Information Update: 12 May 2004

Price : $50

At a glance

  • Originator Roche
  • Class Antiemetics
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 12 May 2004 Discontinued - Phase-I for Emesis in Switzerland (unspecified route)
  • 05 Feb 2003 Phase-I clinical trials in Emesis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top